Monoclonal antibody therapy is a kind of immunotherapy that empowers the body’s immune system to attack cancer cells.
Researchers are applying the knowledge they’ve gained in previous clinical trials as they look into how immunotherapy might provide additional treatment options for patients with recurrent cervical cancer.
“Living” drugs consist of fully functional cells that have been selected and often modified to treat specific diseases, such as cancer. CAR T-cell therapy and therapeutic vaccines fall into this category.
So far, CDK4/6 inhibitors have been shown to be most effective in treating advanced estrogen-receptor positive, HER2-negative breast cancer.
Immunotherapy is a kind of treatment that has had stunning results in some patients with cancers like melanoma, lymphoma, and kidney cancer. Immunotherapy drugs empower the body’s immune system by enabling the body to fight cancer — an approach that can slow or halt cancer in certain patients. In our latest podcast series, The Science … Continued
Precision medicine and immunotherapy are changing the landscape of cancer treatment. The aim of precision medicine, sometimes called personalized medicine, is to match treatments to individual patients taking into account their genetic makeup, medical history, test results, and other distinctive characteristics. Unlike precision medicine, immunotherapy is a particular form of treatment, aimed at manipulating the patient’s … Continued
It’s not uncommon for cancer patients to take to a pen after a diagnosis. Peter Rooney’s taken that to another level. Rooney, a former journalist and author of the book Die Free, captured his cancer journey in the new book Immunopatient: The New Frontier of Curing Cancer. The following excerpt is reprinted with permission from Immunopatient by … Continued
The approval of a targeted therapy and an immunotherapy drug for some patients with advanced stomach cancer reflects recent new approaches to this difficult-to-treat cancer that hasn’t had many therapeutic advances in recent years. Stomach cancer, uncommon in the United States but a leading cause of cancer death globally, causes few definitive symptoms in early … Continued
Small cell lung cancer is the most aggressive type of lung cancer. Unlike its far more common counterpart, non-small cell lung cancer, treatment with immunotherapy drugs hasn’t yet been approved for small cell lung cancer, but some early findings in clinical trials suggest this type of treatment may have potential. Small cell lung cancer gets … Continued
A cancer can be inoperable for a variety of reasons. “Liquid cancers,” such as leukemia, lymphoma, and multiple myeloma, are considered inoperable by nature, because they involve cells or tissues that are dispersed throughout the body. Leukemia and multiple myeloma, for example, originate in abnormal cells of the bone marrow, the spongy material within the … Continued
This originally appeared on Vector, Boston Children’s Hospital’s blog. A novel screening method using CRISPR-Cas9 genome editing technology has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy. The method, developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, uses CRISPR-Cas9 … Continued
In the past, treating cancers involved classifying them primarily by the organ or tissue where they arose – like the skin, the lungs, the breast, or the colon. Today, it’s often possible to identify the genes and proteins responsible for a tumor’s growth, and, in some cases, to offer a drug treatment that specifically targets … Continued
In 1947, when Dana-Farber Cancer Institute founder Sidney Farber, MD, set out to find a drug treatment for childhood leukemia, cancer treatment took two forms – surgery to cut out cancerous masses, and radiation therapy to burn them out. Cancers that couldn’t be removed or irradiated – either because of their position in the body, because … Continued
Immunotherapy refers to treatments that use the body’s own immune system to combat diseases. While no immunotherapy drugs are currently approved for breast cancer, clinical trials at Dana-Farber and elsewhere are exploring the effectiveness of these drugs — and whether they could work in combination with other cancer therapies. “I think we’re going to make … Continued
Vaccines, drugs, and modified human cells that activate the immune system against cancer have improved outcomes and prolonged lives in some types of cancer in the past few years. For patients with glioblastoma, the most common primary brain tumor in adults, immunotherapy has shown some promise in clinical trials — but it can’t yet be … Continued
While new types of immunotherapy are being used to treat a wide variety of cancers, immunotherapy has been a front-line treatment for lymphoma for decades. Lymphoma occurs when white blood cells known as lymphocytes grow abnormally. There are nearly 70 subtypes of Hodgkin lymphoma and non-Hodgkin lymphoma that have been defined. The type of immunotherapy … Continued
Immunotherapy has revolutionized the treatment of many types of cancer and is now undergoing testing in ovarian cancer. Clinical trials of drugs known as immune checkpoint inhibitors, which can unleash a potent immune system attack on cancer cells, have produced remissions in about 10-15 percent of patients with advanced and recurrent ovarian cancer – somewhat … Continued
It’s a compelling idea that has attracted scientists for decades: rather than poison tumors with chemicals and radiation, use a biological agent – a vaccine – to rally the body’s formidable immune defenders to kill cancer cells and shrink tumors. Yet, even as other forms of immunotherapy are showing promise against some cancers, efforts to … Continued
There has been much excitement in recent years around new drugs that exploit the power of the body’s immune system to fight cancer. In some patients, even with advanced cancers, these immunotherapy treatments have slowed or halted the disease after standard treatments no longer worked, with remissions lasting several years and patients experiencing less severe … Continued
While blood cancers known as adult histiocytic disorders are very rare and many patients do well with today’s treatments, researchers are working to improve outcomes with therapies targeted to newly discovered mutations – and they are about to begin testing immunotherapies, too. Histiocytic disorders involved overproduction of immune white cells, histiocytes, that attack tissues in … Continued